At a Glance
- Company: Novo Nordisk; partner: Vivtex
- Location: Novo (Denmark); Vivtex (Shanghai, China)
- Deal value: $2.1B (upfront + milestones + royalties)
- Focus area: Oral peptide therapeutics for cardiometabolic diseases
- Next steps: IND filings 2027; phase 1 trials
What happened?
Novo Nordisk announced a $2.1 billion collaboration with Vivtex on 25 February 2026 to develop oral biologics for obesity-related comorbidities including NASH, heart failure and CKD. The deal includes upfront payments, development/regulatory milestones and tiered royalties, with Novo gaining global rights outside Greater China.
Why does it matter?
GLP-1s transformed obesity/diabetes but comorbidities persist; oral biologics offer needle-free convenience over injectables, expanding total addressable market beyond 100M patients. Vivtex’s platform could yield half-life extended peptides with superior absorption, positioning Novo to dominate oral cardiometabolics.
Who’s behind it?
Novo Nordisk leads GLP-1 dominance; Vivtex pioneers oral biologic delivery via proprietary absorption enhancers. CEOs highlighted complementary strengths in peptide engineering and commercial scale.
How was it achieved?
Vivtex’s platform modifies peptides for gastrointestinal stability and uptake without enzymatic degradation. Preclinical candidates show single-digit bioavailability; deal covers multiple assets with proof-of-mechanism in animal models for NASH fibrosis and cardiac remodelling.
What’s next?
Lead candidates enter IND-enabling studies 2026, phase 1 2027. Novo funds development to proof-of-concept; Vivtex retains China rights. Potential combo with semaglutide eyed for 2029 launch.